These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34503108)

  • 21. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
    J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
    Borodovsky A; Meeker AK; Kirkness EF; Zhao Q; Eberhart CG; Gallia GL; Riggins GJ
    J Neurooncol; 2015 Feb; 121(3):479-87. PubMed ID: 25471051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
    Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
    Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
    Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
    Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
    Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
    Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
    Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
    Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF
    Wang W; Wang M; Jiang H; Wang T; Da R
    BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactate dehydrogenase A silencing in IDH mutant gliomas.
    Chesnelong C; Chaumeil MM; Blough MD; Al-Najjar M; Stechishin OD; Chan JA; Pieper RO; Ronen SM; Weiss S; Luchman HA; Cairncross JG
    Neuro Oncol; 2014 May; 16(5):686-95. PubMed ID: 24366912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Da R; Wang M; Jiang H; Wang T; Wang W
    Front Oncol; 2020; 10():531968. PubMed ID: 33489866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 36. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
    Robinson C; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.